Skip to main content
. 2022 Oct;10(20):1091. doi: 10.21037/atm-22-1353

Table 2. Univariate and multivariate competing risk analyses to identify independent risk factors for time to recurrence in patients with HCC beyond Milan criteria.

Variable Univariate analysis Multivariate analysis
sHR (95% CI) P value sHR (95% CI) P value
Gender (female) 0.89 (0.35–2.24) 0.810 NA NA
Age (>50 years) 0.88 (0.48–1.62) 0.690 NA NA
HBsAg (positive) 1.90 (0.75–4.78) 0.170 NA NA
AFP (>400 ng/mL) 3.19 (1.72–5.91) <0.001 2.33 (1.27–4.26) 0.006
PIVKA-II (>100 mAU/mL) 2.56 (1.18–5.56) 0.018 1.97 (0.85–4.57) 0.120
Child-Pugh class (B-C) 1.36 (0.69–2.65) 0.370 NA NA
Cirrhosis (yes) 0.72 (0.37–1.41) 0.330 NA NA
Tumor size (>5 cm) 1.72 (0.94–3.16) 0.078 NA NA
Tumor number (multiple) 0.77 (0.30–2.02) 0.600 NA NA
Edmondson stage (III-IV) 2.43 (1.25–4.72) 0.009 2.00 (1.00–4.00) 0.050
mVI (yes) 2.18 (1.05–4.53) 0.037 1.20 (0.52–2.79) 0.660
Preoperative TACE 1.27 (0.69–2.33) 0.450 NA NA
Duration of surgery (minutes) 1.00 (0.99–1.00) 0.380 NA NA
Blood loss (mL) 0.97 (0.93–1.01) 0.120 NA NA
Warm ischemic time (minutes) 1.00 (1.00–1.00) 0.850 NA NA
Lenvatinib (yes) 0.40 (0.17–0.92) 0.032 0.33 (0.13–0.83) 0.018

AFP, alpha-fetoprotein; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; NA, not applicable; mVI, microvascular invasion; PIVKA-II, protein induced by vitamin K absence or antagonist-II; sHR, sub-hazard ratio; TACE, transarterial chemoembolization.